| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Over the last 12 months, insiders at InMed Pharmaceuticals Inc. have bought $0 and sold $0 worth of InMed Pharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at InMed Pharmaceuticals Inc. have bought $42,420 and sold $42 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 37,500 shares for transaction amount of $14,625 was made by HULL ANDREW (director) on 2024‑02‑21.
| 2024-07-31 | Sale | MANCINI ALEXANDRA DIANE JANET | Consultant | 240 0.0021% | $0.18 | $42 | -9.52% | |
| 2024-02-21 | HULL ANDREW | director | 37,500 0.6036% | $0.39 | $14,625 | -36.06% | ||
| 2024-02-20 | ADAMS ERIC A | President & CEO | 41,600 0.6841% | $0.36 | $14,922 | -30.98% | ||
| 2022-04-14 | ADAMS ERIC A | President & CEO | 14,160 0.1034% | $0.89 | $12,659 | -75.65% | ||
| 2022-04-13 | ADAMS ERIC A | President & CEO | 8,560 0.06% | $0.85 | $7,276 | -74.83% | ||
| 2022-01-24 | COLWILL BRUCE | CFO | 5,000 0.0326% | $1.09 | $5,439 | -65.32% | ||
| 2022-01-06 | Johnson Shane Aaron | SVP, GM of BayMedica LLC | 8,500 0.0587% | $1.26 | $10,710 | -63.57% | ||
| 2021-12-30 | Johnson Shane Aaron | SVP, GM of BayMedica LLC | 8,093 0.0579% | $1.33 | $10,736 | -63.51% | ||
| 2021-11-15 | Johnson Shane Aaron | SVP, GM of BayMedica LLC | 5,000 0.0369% | $1.37 | $6,845 | -43.28% | ||
| 2021-09-29 | ADAMS ERIC A | President & CEO | 8,800 0.0694% | $1.73 | $15,224 | -51.43% | ||
| 2021-09-28 | ADAMS ERIC A | President & CEO | 11,400 0.0911% | $1.75 | $19,984 | -51.30% | ||
| 2021-09-28 | COLWILL BRUCE | CFO | 5,000 0.0403% | $1.77 | $8,840 | -51.30% |
| Johnson Shane Aaron | SVP, GM of BayMedica LLC | 304595 16.8291% | $249,767.90 | 3 | 0 | <0.0001% |
| ADAMS ERIC A | President & CEO | 43959 2.4288% | $36,046.38 | 5 | 0 | <0.0001% |
| HULL ANDREW | director | 38258 2.1138% | $31,371.56 | 1 | 0 | |
| COLWILL BRUCE | CFO | 11515 0.6362% | $9,442.30 | 2 | 0 | <0.0001% |
| MANCINI ALEXANDRA DIANE JANET | Consultant | 0 0% | $0 | 0 | 1 |
$1,848,072 | 66 | -14.67% | $2.53M | |
$53,490,060 | 55 | 19.35% | $3.25M | |
$1,138,733 | 28 | -4.94% | $3.48M | |
$337,688 | 19 | -33.30% | $2.38M | |
$8,079,884 | 14 | -43.20% | $1.24M | |
$389,864 | 11 | 12.52% | $2.38M | |
$82,890 | 11 | -16.74% | $1.96M | |
$18,269 | 10 | -21.15% | $2.76M | |
$126,023 | 10 | -66.17% | $1.52M | |
$7,268,979 | 7 | -48.44% | $2.37M | |
InMed Pharmaceuticals Inc. (INM) | $70,828 | 6 | -57.96% | $1.48M |
$726,438 | 4 | -72.85% | $1.17M | |
$553,551 | 4 | -74.30% | $883,437.00 | |
$149,778 | 4 | -45.16% | $3.27M | |
$23,454 | 1 | -99.16% | $7,341.00 | |
$1,049,630 | 1 | -74.91% | $865,577.00 | |
$37,000 | 1 | 79.42% | $4.09M | |
$9,963 | 1 | -14.25% | $2.31M | |
$19,863 | 1 | 144.27% | $862,373.00 |
| Increased Positions | 3 | +21.43% | 25,108 | +8.27% |
| Decreased Positions | 5 | -35.71% | 101,648 | -33.48% |
| New Positions | 3 | New | 25,108 | New |
| Sold Out Positions | 4 | Sold Out | 83,283 | Sold Out |
| Total Postitions | 12 | -14.29% | 227,050 | -25.21% |
| Sabby Management, Llc | $246.00 | 7.33% | 219,998 | +219,998 | New | 2025-09-30 |
| Drw Securities, Llc | $40.00 | 1.2% | 35,865 | +35,865 | New | 2025-09-30 |
| Virtu Financial Llc | $23.00 | 0.68% | 20,369 | +20,369 | New | 2025-09-30 |
| Renaissance Technologies Llc | $19.00 | 0.56% | 16,800 | +16,800 | New | 2025-09-30 |
| Thompson Davis & Co., Inc. | $11.00 | 0.34% | 10,249 | +10,249 | New | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | 0.01% | 300 | 0 | 0% | 2025-09-30 |
| Banque Cantonale Vaudoise | $0 | 0% | 6 | 0 | 0% | 2025-09-30 |
| Federation Des Caisses Desjardins Du Quebec | $0 | 0% | 2 | +<1 | New | 2025-09-30 |
| Allsquare Wealth Management Llc | $0 | 0% | 1 | 0 | 0% | 2025-06-30 |
| Bessemer Group Inc | $0 | 0% | 0 | <1 | Sold Out | 2025-09-30 |